Business-as-Usual will not Deliver the COVID-19 Vaccines We Need

被引：3
作者：
Torreele E. [1 ]
机构：
[1] Institute for Innovation and Public Purpose (IIPP), University College London, London
来源：
Development | 2020年 / 63卷 / 2-4期
关键词：
Collective intelligence; Medical innovation; Open science; R&D governance; Transparency; Vaccination; Vaccine safety and efficacy;
D O I：
10.1057/s41301-020-00261-1
中图分类号：
学科分类号：
摘要：
Governments must become active shapers of medical innovation and drive the development of critical health technologies as global health commons. The ‘race’ for COVID-19 vaccines is exposing the deficiencies of a business-as-usual medical innovation ecosystem driven by corporate interests, not health outcomes. Instead of bolstering collective intelligence, it relies on competition between proprietary vaccines and allows the bar on safety and efficacy to be lowered, risking people’s health and undermining their trust. © 2020, Society for International Development.
引用
收藏
页码：191 / 199
页数：8
相关论文
共 31 条
[1]  
Nsikan A., Moderna’s mRNA vaccine reaches its final phase, Here’s How It Works, National Geographic, (2020)
[2]  
Avorn J., Kesselheim A., Regulatory Decision-making on Covid-19 Vaccines During a Public Health Emergency, JAMA, 324, 13, pp. 1284-1285, (2020)
[3]  
Bartsch S., O'Shea K., Ferguson M., Bottazzi M., Wedlock P., Strych U., McKinnell J., Siegmund S., Cox S., Hotez P., Lee B., Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention, American Journal of Preventive Medicine, 59, 4, pp. 493-503, (2020)
[4]  
Stewart B., The erosion of public sector vaccine production. The case of the Netherlands, The Politics of Vaccination, (2017)
[5]  
Brown D., Medicine for All: The Case for a Public Option in The Pharmaceutical Industry, (2020)
[6]  
Callaway E., The unequal scramble for coronavirus vaccines—by the numbers, Nature, 24 August, (2020)
[7]  
Cameron N., The government agency that made silicon Valley, Unherd, (2018)
[8]  
Doshitopol P., These Coronavirus Trials Don’t Answer the One Question We Need to Know, New York Times 22 Sept, (2020)
[9]  
Everson-Stewart S., Emerson S.S., Bio-creep in non-inferiority clinical trials, Statistics in Medicine, 29, 27, pp. 2769-2780, (2010)
[10]  
Fletcher E., World Health Assembly Approves Milestone Resolution On Price Transparency, Health Policy Watch, (2019)
1234